Early hypophosphataemia and refeeding syndrome in extremely low birthweight babies and outcomes to 2 years of age: secondary cohort analysis from the ProVIDe trial.

Objective: To investigate in extremely low birthweight (ELBW; <1000 g) babies the associations between refeeding syndrome (serum phosphate <1.4 mmol·L and serum total calcium>2.8 mmol·L) and hypophosphataemia in the first week and death or neurodisability at 2 years' corrected age (CA).